MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 6, 2007; DOI: 10.1124/mol.107.038877


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.038877v1
73/2/349    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jorgensen, R.
Right arrow Articles by Elling, C. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jorgensen, R.
Right arrow Articles by Elling, C. E


Received for publication June 7, 2007.
Revised October 26, 2007.
Accepted for publication November 6, 2007.

Characterization of G-Protein Coupled Receptor Kinase Interaction with the NK-1 Receptor Using BRET

Rasmus Jorgensen 1, Nicholas D Holliday 2, Jakob L Hansen 3, Milka Vrecl 4, Anders Heding 1, Thue W Schwartz 5, Christian E Elling 1*

1 7TM Pharma 2 University of Nottingham 3 University of Copenhagen 4 University of Ljubljana, Slovenia 5 7TM Pharma / University of Copenhagen

* Address correspondence to: E-mail: cee{at}7tm.com

Abstract

To analyze the interaction between the Neurokinin-1 (NK-1) receptor and G-protein coupled receptor kinases (GRKs), we performed Bioluminescence Resonance Energy Transfer2 (BRET2) measurements between the family A NK-1 receptor and GRK2 and GRK5 as well as their respective kinase-inactive mutants. We observed agonist induced interaction of both GRK5 and GRK2 to the activated NK-1 receptor. In saturation experiments we observed GRK5 to interact with the activated receptor in a monophasic manner while GRK2 interacted in a biphasic manner with the low affinity phase corresponding to receptor affinity for GRK5. Agonist induced GRK5 interaction with the receptor was dependent on intact kinase-activity while the high affinity phase of GRK2 interaction was independent of kinase activity. Surprisingly, BRET2 saturation experiments indicated that before receptor activation, the full length NK-1 receptor, but not a functional C-terminal tail truncated receptor, is pre-associated with GRK5 in a relatively low affinity state. We demonstrate that GRK5 can compete for agonist induced GRK2 interaction with the NK-1 receptor while GRK2 does not compete for receptor interaction with GRK5. We suggest that GRK5 is pre-associated with the NK-1 receptor and that GRK5, rather than GRK2, is a key player in competitive regulation of GRK subtype specific interaction with the NK-1 receptor.


Key words: Tachykinin, Gs family, Gq/11 family, Desensitization/uncoupling, GRKs, barrestins





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics